Effective delivery of mycophenolic acid by oxygen nanobubbles for modulating immunosuppression.
Animals
Biological Availability
Cell Line, Tumor
Cytokines
/ metabolism
Drug Carriers
/ chemistry
Humans
Immunosuppression Therapy
Immunosuppressive Agents
/ pharmacology
Inflammation
/ drug therapy
Leukocytes, Mononuclear
Mice
Mycophenolic Acid
/ pharmacology
Nanoparticles
/ chemistry
Oxygen
/ chemistry
autoimmune diseases
immunosuppression
inflammation
mycophenolic acid
oxygen nanobubbles
peripheral blood mononuclear cells
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
11
2019
accepted:
19
01
2020
entrez:
1
4
2020
pubmed:
1
4
2020
medline:
19
5
2021
Statut:
epublish
Résumé
Immunosuppressive drugs are crucial for preventing acute graft rejection or autoimmune diseases. They are generally small molecules that require suitable drug carriers for ensuring stability, bioavailability, and longer half-life. Mycophenolic acid (MPA) is an extensively studied immunosuppressive drug. However, it requires suitable carriers for overcoming clinical limitations. Currently, lipid-shelled micro- and nanobubbles are being thoroughly investigated for diagnostic and therapeutic applications, as they possess essential properties, such as injectability, smaller size, gaseous core, high surface area, higher drug payload, and enhanced cellular penetration. Phospholipids are biocompatible and biodegradable molecules, and can be functionalized according to specific requirements.
Identifiants
pubmed: 32226527
doi: 10.7150/thno.41850
pii: thnov10p3892
pmc: PMC7086369
doi:
Substances chimiques
Cytokines
0
Drug Carriers
0
Immunosuppressive Agents
0
Mycophenolic Acid
HU9DX48N0T
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3892-3904Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18351-2
pubmed: 24187149
Mol Aspects Med. 2016 Feb-Mar;47-48:24-34
pubmed: 26768963
J Pharmacol Exp Ther. 2007 Nov;323(2):675-83
pubmed: 17726158
J Immunol. 2001 Jun 1;166(11):6952-63
pubmed: 11359857
Nat Rev Drug Discov. 2003 Oct;2(10):803-11
pubmed: 14526383
Autoimmun Rev. 2007 Jan;6(3):190-5
pubmed: 17289556
Nanomaterials (Basel). 2019 Jan 02;9(1):
pubmed: 30609703
Inflammation. 2018 Jun;41(3):1008-1020
pubmed: 29455288
Biochem J. 2006 Jun 15;396(3):517-27
pubmed: 16533170
J Interferon Cytokine Res. 2005 Jun;25(6):297-310
pubmed: 15957953
Exp Cell Res. 2009 Jul 1;315(11):1791-7
pubmed: 19332053
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 Jul-Aug;5(4):329-45
pubmed: 23504911
Ophthalmology. 1999 Feb;106(2):370-4
pubmed: 9951492
Colloids Surf B Biointerfaces. 2016 Jun 1;142:290-296
pubmed: 26966999
Cytokine. 1992 May;4(3):239-48
pubmed: 1498259
Adv Drug Deliv Rev. 2004 May 7;56(9):1291-314
pubmed: 15109770
Shock. 2019 Dec;52(6):612-621
pubmed: 30601332
Mini Rev Med Chem. 2017;17(9):734-745
pubmed: 27903231
J Biomed Sci. 2017 Aug 24;24(1):60
pubmed: 28836970
Catheter Cardiovasc Interv. 2005 Dec;66(4):491-5
pubmed: 16283680
Theranostics. 2014 Sep 05;4(11):1133-44
pubmed: 25250094
Int J Pharm. 2013 Nov 1;456(1):223-34
pubmed: 23973508
J Immunol. 2010 Apr 15;184(8):4062-8
pubmed: 20368286
Virology. 2002 Dec 20;304(2):211-21
pubmed: 12504563
Front Immunol. 2018 Oct 31;9:2532
pubmed: 30429857
Nat Rev Drug Discov. 2009 Feb;8(2):139-52
pubmed: 19165233
Adv Healthc Mater. 2013 Aug;2(8):1131-41
pubmed: 23471884
Int J Cancer. 2016 Mar 1;138(5):1058-66
pubmed: 25784597
Nature. 2008 Jun 5;453(7196):807-11
pubmed: 18432192
Trends Mol Med. 2019 Jan;25(1):33-46
pubmed: 30442494
J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):445-9
pubmed: 9308561
Ther Deliv. 2016;7(2):117-38
pubmed: 26769397
Molecules. 2018 Aug 31;23(9):
pubmed: 30200336
Soft Matter. 2015 Mar 21;11(11):2067-79
pubmed: 25698443
Int J Pharm. 2009 Nov 3;381(2):160-5
pubmed: 19616610
Sci Rep. 2017 Aug 25;7(1):9481
pubmed: 28842713
N Engl J Med. 2011 Feb 17;364(7):656-65
pubmed: 21323543
Br J Surg. 2000 Oct;87(10):1346-51
pubmed: 11044159
Cell. 2003 Mar 7;112(5):645-57
pubmed: 12628185
PLoS Pathog. 2018 Oct 31;14(10):e1007405
pubmed: 30379932
Adv Drug Deliv Rev. 2008 Jun 30;60(10):1153-66
pubmed: 18486268
Clin Immunol. 2015 Sep;160(1):24-35
pubmed: 25937032
Sci Rep. 2016 Jun 08;6:27711
pubmed: 27270556
J Biomed Mater Res B Appl Biomater. 2014 Aug;102(6):1148-56
pubmed: 24425069
Blood. 2005 Jan 15;105(2):697-702
pubmed: 15353479
J Immunol. 2019 Sep 1;203(5):1298-1312
pubmed: 31358659
J Clin Invest. 2013 Apr;123(4):1741-9
pubmed: 23454752
Theranostics. 2019 Jan 1;9(1):126-151
pubmed: 30662558
Drug Dev Ind Pharm. 2019 Jan;45(1):76-87
pubmed: 30169982
Pediatr Nephrol. 2017 Aug;32(8):1315-1322
pubmed: 27312386
Biomaterials. 2016 May;89:1-13
pubmed: 26946401
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S318-S327
pubmed: 30032670
Sci Rep. 2017 Jul 24;7(1):6318
pubmed: 28740226
Int J Nanomedicine. 2014 Sep 23;9:4495-505
pubmed: 25285003
J Control Release. 2015 Jul 10;209:139-49
pubmed: 25913365
J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):957-60
pubmed: 10365927